<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32446">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684279</url>
  </required_header>
  <id_info>
    <org_study_id>SEP360-322</org_study_id>
    <nct_id>NCT02684279</nct_id>
  </id_info>
  <brief_title>Dasotraline Binge Eating Disorder Extension Study</brief_title>
  <official_title>An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Binge Eating Disorder Extension Study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, 12 month, multicenter, open-label, flexibly-dosed, safety study in adults
      with Binge Eating Disorder.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of overall Adverse Events, Serious Adverse Events (SAEs), and AEs (or SAEs) leading to discontinuation</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The frequency and severity of suicidal ideation and suicidal behavior using the Columbia Suicide Severity Rating Scale (C SSRS)</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory evaluations (serum chemistry, hematology, urinalysis)</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluations (vital signs including orthostatic effects, and 12 lead ECGs)</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of suicidal ideation and suicidal behavior using the C-SSRS</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in body weight</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Body Mass Index</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting lipid panel (triglycerides, total cholesterol, high-density lipoprotein [HDL] cholesterol, and low-density lipoprotein [LDL] cholesterol)</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin A1c levels</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose levels</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the symptoms of withdrawal from dasotraline from Week 52/EOT as measured by: Cocaine Selective Severity Assessment (CSSA) total score at Weeks 53, 54, and 55</measure>
    <time_frame>Up to 55 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the symptoms of withdrawal from dasotraline from Week 52/End of treatment (EOT) as measured by: - Discontinuation-Emergent Signs And Symptoms (DESS) total score at Weeks 53, 54, and 55</measure>
    <time_frame>Up to 55 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the symptoms of withdrawal from dasotraline from Week 52/End of treatment (EOT) as measured by -Hamilton Anxiety Rating Scale (HAM A) total score at Weeks 53, 54, and 55</measure>
    <time_frame>Up to 55 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the symptoms of withdrawal from dasotraline from Week 52/End of treatment (EOT) as measured by: - Montgomery-Asberg Depression Rating Scale (MADRS) total score at Weeks 53, 54, and 55</measure>
    <time_frame>Up to 55 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eating Disorder Examination Questionnaire Modified (EDE Q) modified total score</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression-Severity (CGI S) score</measure>
    <time_frame>Baseline to12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sheehan disability Scale (SDS) total score and subscale scores (school/work disability, social life disability, and family life disability)</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Binge Eating Disorder</condition>
  <arm_group>
    <arm_group_label>Dasotraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4, 6, 8 mg flexibly dosed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasotraline</intervention_name>
    <description>Dasotraline 4, 6, 8 mg flexibly dosed once daily</description>
    <arm_group_label>Dasotraline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of the treatment period of a dasotraline core study (ie, SEP360 221) for
             the treatment of BED.

          -  Subject has agreed to participate by providing written informed consent and is
             willing and able to comply with the protocol, in the opinion of the investigator.

          -  Subject has not taken any medication other than the study drug for the purpose of
             controlling BED symptoms during the core study.

          -  Female subject must have a negative urine pregnancy test at open label (OL) Baseline;
             females who are post-menopausal (defined as at least 12 months of spontaneous
             amenorrhea) and those who have undergone hysterectomy or bilateral oophorectomy will
             be exempted from the pregnancy test.

          -  Female subject of childbearing potential and male subject with female partner of
             childbearing potential must agree to use an effective and medically acceptable form
             of birth control (see Section 22, Appendix III) throughout the study period. Note:
             Continued use of an effective and medically acceptable form of birth control is
             recommended for 30 days after study completion.

          -  Subject is judged by the investigator to be suitable for participation in a 12 month
             clinical trial involving open-label dasotraline treatment.

          -  Subject can read well enough to understand the informed consent form and other
             subject materials.

        Exclusion Criteria:

          -  Subject is considered by the investigator to be at imminent risk of suicide, injury
             to self or to others, or damage to property.

          -  Subject answers &quot;yes&quot; to &quot;suicidal ideation&quot; item 4 (active suicidal ideation with
             some intent to act, without specific plan) or item 5 (active suicidal ideation with
             specific plan and intent) on the C SSRS assessment at OL Baseline. Subjects who
             answer &quot;yes&quot; to this question must be referred to the Investigator for follow up
             evaluation.

          -  Subject has a clinically significant abnormality including physical examination,
             vital signs, ECG, or laboratory tests that the investigator in consultation with the
             medical monitor considers to be inappropriate to allow participation in the study.

          -  Subject has a positive urine drug screen (UDS) or breath alcohol test at OL Baseline.

          -  Subject is breastfeeding.

          -  Subject is at high risk of non-compliance in the investigator's opinion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>56 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dasotraline Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dasotraline Medical Director</last_name>
    <phone>1-866-503-6351</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California Research</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brock Summers</last_name>
      <phone>424-284-3171</phone>
      <email>bhsummers@sbcglobal.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Grosz</last_name>
      <phone>818-705-7451</phone>
      <email>Dgrosz@priresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative NeuroScience Network Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walling</last_name>
      <phone>714-799-7799</phone>
      <email>davidwalling@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don DeFrancisco</last_name>
      <phone>949-752-7936</phone>
      <email>ddefrancisco@priresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Duffy</last_name>
      <phone>714-542-3008</phone>
      <email>JohnGDuffyMD@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weiss and Lytle, PLLC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209*</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Weiss</last_name>
      <phone>720-941-9363</phone>
      <email>dbweissmd@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Mark Joyce, MD</last_name>
      <phone>904-281-5757</phone>
      <email>mjoyce@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>John Mark Joyce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Segal</last_name>
      <phone>305-722-8444</phone>
      <email>ssegal@segalinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Scott Segal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Harper</last_name>
      <phone>407-425-5100</phone>
      <email>lharper@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Linda Harper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Americo Padilla, MD</last_name>
      <phone>305-279-0015</phone>
      <email>Americo.Padilla@qps.com</email>
    </contact>
    <investigator>
      <last_name>Americo Padilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Advanced Medical Research</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Sambunaris</last_name>
      <phone>770-817-9200</phone>
      <email>a.sambunaris@atlanta-institute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuotrials Research, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Rosenberg</last_name>
      <phone>404-851-9934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capstone Clinical Research</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Greenbaum</last_name>
      <phone>847-549-7214</phone>
      <email>mgreenbaum@capstoneclinical.com</email>
    </contact>
    <investigator>
      <last_name>Michael Greenbaum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goldpoint Clinical Research, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Saini</last_name>
      <phone>317-229-6202</phone>
      <email>Rsaini@goldpointcr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cyress Medical Research Center, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jefferey Davis</last_name>
      <phone>316-425-6333</phone>
      <email>jeff@rairiehealthwellness.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Hudson</last_name>
      <phone>617-855-2911</phone>
      <email>jhudson@mclean.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adams Clinical Trials, LLC</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rutrick</last_name>
      <phone>617-744-8542</phone>
      <email>drutrick@adamsclinical.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Rutrick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Charles Psychiatric Associates - Midwest Research Group</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Mattingly</last_name>
      <phone>636-946-8032</phone>
      <email>drmattingly@midwestresearchgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princeton Medical Institute, LCC</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Apter</last_name>
      <phone>609-921-3555</phone>
      <phone_ext>17</phone_ext>
      <email>jtapter@gminstitutes.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bioscience Research, LLC</name>
      <address>
        <city>Mt. Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Krakow</last_name>
      <phone>914-385-0200</phone>
      <email>dsk@drkrakow.com</email>
    </contact>
    <investigator>
      <last_name>David Krakow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne Harper</last_name>
      <phone>919-781-2514</phone>
      <email>wharper@wakeresearch.com</email>
    </contact>
    <investigator>
      <last_name>Wayne Harper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Rhee</last_name>
      <phone>330-252-1500</phone>
      <email>MargaretRhee@RadiantResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Patient Priority Clinical Sites</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janell Lundgren</last_name>
      <phone>513-791-7760</phone>
      <email>jlundgren@patientpriority.com</email>
    </contact>
    <investigator>
      <last_name>Janell Lundgren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otto Dueno</last_name>
      <phone>937-424-1050</phone>
      <email>odueno@midwestclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lindner Center Of Hope</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan McElroy</last_name>
      <phone>513-536-4673</phone>
      <email>susan.mcelroy@lindnercenter.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Thurman</last_name>
      <phone>405-235-8188</phone>
      <email>lthurman@ipsresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunstone Medical Research, LLC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clark Cullen</last_name>
      <phone>541-973-2080</phone>
      <email>clarkc@sunstoneresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigatons, INC.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beal Essink</last_name>
      <phone>503-276-6224</phone>
      <email>portland@occi.org</email>
    </contact>
    <investigator>
      <last_name>Beal Essink</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigations, Inc.</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Horwitz</last_name>
      <phone>509-540-0100</phone>
      <email>Salem@occi.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lehigh Center For Clinical Research</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Gross</last_name>
      <phone>610-820-0342</phone>
      <email>pgross@lehighcenter.com</email>
    </contact>
    <investigator>
      <last_name>Paul Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Geisberg</last_name>
      <phone>864-261-9563</phone>
      <email>harrygeisberg@radiantresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radient Research, Inc.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Ellison</last_name>
      <phone>864-877-9239</phone>
      <email>williamellison@radiantresearch.com</email>
    </contact>
    <investigator>
      <last_name>William Ellison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shonna Piegari</last_name>
      <phone>713-838-2022</phone>
      <email>shonna.piegari@tcddresearch.com</email>
    </contact>
    <investigator>
      <last_name>Shonna Piegari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psychiatric Medical Associates</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sejal Mehta</last_name>
      <phone>972-267-1988</phone>
      <email>smehta@raasites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Johnston</last_name>
      <phone>801-261-8930</phone>
      <email>markjohnston@radiantresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Associates</name>
      <address>
        <city>Woodstock</city>
        <state>Vermont</state>
        <zip>05091</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Groft</last_name>
      <phone>802-457-4904</phone>
      <email>agroft@navt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NeuroScience, Inc.</name>
      <address>
        <city>Herndon</city>
        <state>Virginia</state>
        <zip>20170</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Saylor</last_name>
      <phone>703-787-9090</phone>
      <email>ksaylor@neuroscience-inc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Summitt Research Network(Seattle) LLC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Waltman</last_name>
      <phone>206-624-4587</phone>
      <email>clairew@summitnetwork.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>January 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
    <mesh_term>Bulimia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
